Small by design.
Network Immunology is a Vancouver biotechnology company developing AbstimX™, a finite-course two-antibody approach to immune regulation, starting with chronic allergic disease.
We operate with a focused core team and bring in specialist expertise around the work that matters most.
Build the evidence.
Define the product.
Prove what matters next.
Leadership & Directors
-
George has led Network Immunology for over a decade, taking AbstimX from concept to preclinically validated platform therapy with granted patents in the United States, China and Japan and into the veterinary clinical stage. He has led several financing rounds, intellectual property milestones, and the scientific and clinical partnerships the programme depends on. He brings sixteen years of full-time experience in biotech business administration, capital raising and corporate development.
-
Aaron brings fifteen years in health and management consulting, including significant work in animal health. He leads day-to-day operations at Network Immunology, building the systems and structure that keep the science, the programmes and the business moving in the same direction.
-
Douglas brings two decades of corporate development and commercial leadership across biotechnology, life sciences and advanced technology ventures. He has held senior roles building companies from early stage through commercialisation, with a track record of establishing the partnerships and capital relationships that early ventures depend on. He has served on the board of Network Immunology through the development of the AbstimX platform, and contributes on corporate strategy, growth and capital structure.
-
Geoffrey holds a PhD and ran an immunology laboratory at the University of British Columbia, where he developed the symmetrical immune network theory that underlies AbstimX. He is the named inventor on the company's granted patent estate and founded Network Immunology to bring that work toward clinical application.
Advisors
-
Anthony holds over two decades of business, operations, product development, and scientific experience with a sound clinical understanding in personalised Medicine, Drug and Biomarker Development, Health and Wellness (Food), Autoimmunity, Gastroenterology, Pathology, and Oncology.
He has served in corporate development capacities for a number of companies and has a strong aptitude for operations.
-
A financial analyst with over fifteen years of experience in private equity across multiple industries, Miika brings expertise in securities compliance, investor relations and corporate governance. His background in capital markets and regulatory matters supports the company's standards of compliance and transparency with investors and regulators.
-
Kirk brings over two decades across health sciences and biotechnology, spanning clinical operations, regulatory pathways and product development. He runs Network Immunology's programme management, tracking deliverables and keeping the workstreams integrated.
-
Edwin holds a PhD in pathology and laboratory medicine and brings over a decade across clinical research, medical affairs and preclinical development. He supports Network Immunology on scientific strategy, evidence and external scientific relationships.
Built around the work.
NI does not maintain a large standing organization. Specialist expertise is engaged as the program requires it.
Clinical development
Biostatistics
CMC & manufacturing
Intellectual property
Regulatory strategy
Building what the next proof requires.
Designed for adoption, not just efficacy.
A successful treatment has to work for more than the biology.
It has to work for the patient or pet owner, the clinician, the clinic, the payer, the manufacturer and the commercial partner.
Product definition includes the treatment model.
Regimen
Administration
Treatment burden
Clinic workflow
Pricing
Manufacturing
Supply
The patient has to win.
The system around them has to work
